News Image

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Provided By GlobeNewswire

Last update: Nov 18, 2024

- Enhances Aclaris’ pipeline with complementary biologics portfolio -
- Expands leadership team with addition of seasoned biotech executives -
- Management to host conference call today at 8:30 AM ET -

Read more at globenewswire.com

ACLARIS THERAPEUTICS INC

NASDAQ:ACRS (9/12/2025, 8:00:00 PM)

After market: 1.99 +0.04 (+2.05%)

1.95

-0.02 (-1.02%)



Find more stocks in the Stock Screener

Follow ChartMill for more